Simon Cooper
Chief Tech/Sci/R&D Officer presso MORPHIC HOLDING, INC.
Patrimonio netto: - $ in data 31/03/2024
Provenienza dei contatti di primo grado di Simon Cooper
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.
17
| Subsidiary | Biotechnology | 17 |
| Public Company | Pharmaceuticals: Major | 17 | |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
| Public Company | Pharmaceuticals: Major | 2 | |
Anokion US, Inc.
1
| Private Company | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Simon Cooper tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company. The company focuses on the research and clinical development of products to treat allergies, autoimmune diseases, and vaccines for the management of drugs of abuse. It was founded on March 26, 1987 and is headquartered in Woburn, MN. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| THE GOLDMAN SACHS GROUP, INC. | Investment Banks/Brokers | Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ACCELERON PHARMA INC. | Biotechnology | Chief Operating Officer | |
| TRANSLATE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Compliance Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
Periodontix, Inc.
 Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| Bentley University | College/University | Undergraduate Degree Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree Doctorate Degree | |
| Tufts University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
| University of New Hampshire | College/University | Graduate Degree | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member | |
| SCHRÖDINGER, INC. | Packaged Software | Corporate Officer/Principal | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Canbex Therapeutics Ltd.
 Canbex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| Tuck School of Business at Dartmouth | College/University | Masters Business Admin Masters Business Admin | |
NS Pharma, Inc.
 NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | Pharmaceuticals: Major | President | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
| PROGYNY, INC. | Miscellaneous Commercial Services | Director/Board Member | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Inspirna, Inc.
 Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Quentis Therapeutics, Inc.
 Quentis Therapeutics, Inc. BiotechnologyHealth Technology Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
| RELAY THERAPEUTICS, INC. | Biotechnology | Founder | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Founder Director/Board Member | |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Biotechnology | Director/Board Member | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Institute For Protein Innovation, Inc.
 Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Dewpoint Therapeutics, Inc.
 Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
Quvium UK Ltd.
 Quvium UK Ltd. Medical SpecialtiesHealth Technology Quvium UK Ltd. engages in a medical device company. It specializes in developing constant-use solutions for chronic and acute respiratory conditions. The company was founded by Steven Schmidt and Karen Travers in 2013 and is headquartered in Sandwich, KE. | Medical Specialties | Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
Tectonic Therapeutic, Inc.
 Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | Miscellaneous Commercial Services | Founder Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 44 |
| Regno Unito | 4 |
| Svizzera | 2 |
| Germania | 2 |
| Belgio | 2 |
Settori
| Health Technology | 32 |
| Consumer Services | 11 |
| Commercial Services | 6 |
| Finance | 4 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 218 |
| Corporate Officer/Principal | 82 |
| Independent Dir/Board Member | 53 |
| Chief Executive Officer | 28 |
| Undergraduate Degree | 23 |
Contatti più connessi
| Insiders | |
|---|---|
| Amir Nashat | 49 |
| Martin Edwards | 38 |
| Otello Stampacchia | 37 |
| Nilesh Kumar | 26 |
| Daniel Vasella | 25 |
| Susannah Gray | 20 |
| Joseph Slattery | 18 |
| Timothy Springer | 17 |
| Vikas Goyal | 16 |
| Eric Cornut | 14 |
| Mark Murcko | 14 |
| Gustav Christensen | 14 |
| Praveen Tipirneni | 11 |
| Norbert W. Bischofberger | 11 |
| Alpna Seth | 11 |
- Borsa valori
- Insiders
- Simon Cooper
- Connessioni Società
